#United States #Cambridge #J.P. Morgan #Marengo Therapeutics #Invikafusp Alfa

Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Marengo Therapeutics, Inc., a pioneering name in the clinical-stage biotechnology landscape, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event, which is one of the most significant gatherings in the healthcare sector, will include a presentation by Dr. Zhen Su, the CEO of Marengo, set to take place on January 16, 2025, at 10 AM PT.

This appearance is particularly exciting, given the recent clinical advancements Marengo has achieved, particularly with its lead asset, Invikafusp alfa (STAR0602). This compound has been pivotal in their research, boasting promising results showcased during the recent Society for Immunotherapy of Cancer (SITC) plenary session. Furthermore, the FDA has granted Fast Track designation for Invikafusp alfa, a significant milestone that showcases the potential impact of their work in the field.

Dr. Su expressed enthusiasm about sharing these developments, stating, "The clinical validation of our TCR Vβ targeted precision dual T cell agonist approach has unlocked the immense potential of the T-cell repertoire in vivo. This could pave the way for transformative therapies across various fields, including oncology, autoimmune diseases, and infectious diseases." The recent anti-tumor activity observed in PD-1 resistant 'cold' tumors provides a silver lining, considering the difficulty in treating such malignancies.

At the J.P. Morgan Healthcare Conference, Marengo plans to delve into the efficacy of Invikafusp alfa in more detail. With its unique mechanism, this therapy has shown single-agent activity against challenging tumor types. Based on current progress, Marengo is poised to advance rapidly through its Phase 2 clinical trials, aiming to provide further insights to the healthcare community later this year.

About Marengo Therapeutics

Founded with a mission to revolutionize cancer therapy, Marengo Therapeutics stands at the forefront of innovation in the biotechnology sector. Utilizing its proprietary Selective T Cell Activation Repertoire (STAR) platform, the company is dedicated to developing novel T Cell Receptor (TCR) targeting antibodies. These targeted therapies are designed to selectively modulate various T cell subsets, which could provide lifelong protection against cancer and a range of other diseases.

The company's passionate team of scientists, who are well-versed in the fields of immunology and oncology, drive the research efforts at Marengo. Their work indicates a strong commitment to applying an extensive understanding of T cell functions and receptor signaling to forge a future where every individual’s immune system can combat cancer effectively.

With the momentum built from its latest achievements and ongoing research, Marengo Therapeutics is confident about progressing swiftly with its clinical programs, focusing on making breakthroughs, that could change the landscape of oncology and improve patient outcomes significantly.

To learn more about their innovative approaches and the science behind their therapies, visit marengotx.com.